Prostate Cancer and Prostatic Diseases

Article	Citations
When precision meets prostate cancer: the rising role of HIFU focal therapy	140
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications	117
Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis	86
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	65
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	63
Variation in communication of side effects in prostate cancer treatment consultations	62
Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study	54
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	54
Goodbye and thanks for the memories	40
Can there be consensus on whether vasectomy is a prostate cancer risk factor?	39
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative	38
Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study)	38
A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location	37
Statins and prostate cancer—hype or hope? The epidemiological perspective	37
Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem?	36
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	32
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	31
Germline alterations among Hispanic men with prostate cancer	31
Concerns regarding prostate cancer screening guidelines in minority populations	30
Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection	30
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy	30
Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study	28
Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model	27
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle	26
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	26

Impact of medical treatment on storage and voiding LUTS, nocturia, and quality of life in men at risk for progression	26
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	26
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	26
Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	26
Impact of diverticular disease on prostate cancer risk among hypertensive men	25
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series	25
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis	24
Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer	24
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer	22
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer	22
EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy	22
Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function	22
Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England	21
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer	21
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN	21
Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis	21
In regard to Boeri et al. ‘Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience’	20
Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic	20
Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled cli	20
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)	20
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	20
The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis	20
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer	20
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	20
Correction to: Advances in PSMA-targeted therapy for prostate cancer	20
Correction: The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction	20
More evidence that physical activity is beneficial for prostate cancer	20
Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysis	19
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones	19
PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer	19
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis	19
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	18
Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases	18
Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number	18
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	18
Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer—exploratory analysis of LATITUDE study	18
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	18
Advancing the treatment of localized prostate cancer with MR-guided radiotherapy	18
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	17
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer	17
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	17
Best of 2022 in prostate cancer and prostatic diseases	17
Nomograms in PCa: where do we stand	17
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	17
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries	17
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415	16
Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis	16
The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement	16
Correction: Public interest in dietary supplements for prostate cancer prevention	16
Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis	16

Prostate cancer metastasis and health disparities: a systematic review	16
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	16
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	16
Usefulness of podcasts to provide public education on prostate cancer genetics	16
The impact of race on survival in metastatic prostate cancer: a systematic literature review	16
Standardizing targeted and perilesional biopsy: considerations and challenges	16
Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients	15
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sens	15
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	15
Clinicogenomic characterization of prostate cancer liver metastases	15
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	15
Artificial intelligence applications in prostate cancer	15
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	15
Comparison of perioperative and short-terms outcomes of en-bloc Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy: a propensity-score matching analysis	14
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	14
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial	14
Nerve-sparing radical prostatectomy using the neurovascular structure-adjacent frozen-section examination (NeuroSAFE): results after 20 years of experience	14
Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases	14
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors	14
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	14
Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes—ready for prime time?	14
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials	14
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007–2022	14
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	14
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	14
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?	14
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board	13
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies	13
Hyperglycemia and microRNAs in prostate cancer	13
The microbiome and prostate cancer	13
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	13
Incidence of prostate cancer in transgender women in the US: a large database analysis	13
Focal therapy for prostate cancer—ready to be a standard of care?	13
Reply to “Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review”	13
Quality of information and appropriateness of ChatGPT outputs for urology patients	13
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	13
RE: “Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?”	13
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs	13
Single-port transvesical simple prostatectomy for the surgical treatment of benign prostatic hyperplasia: functional and continence outcomes	13
Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation	12
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	12
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy	12
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	12
MyProstateScore in men considering repeat biopsy: validation of a simple testing approach	12
Exercise impacts the epigenome of cancer	12
New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy – a comprehensive review	12
Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120	11
The changing face of castrate resistant prostate cancer	11
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	11
Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression	11
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	11
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers	11
Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study	11
Developers-Doctor-patients: the artificial intelligence’s trifecta	11
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	11
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	11
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—a multicenter SEARCH cohort study	11
Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial	10
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	10
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	10
Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC)	10
Integrating risk calculators into routine clinical workflow for the detection of prostate cancer: next steps to achieve widespread adoption	10
Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?	10
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis	10
Statins and prostate cancer—hype or hope? The biological perspective	10
TRexit is going one step further	10
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	10
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men	10
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	10
Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate	9
Length of positive surgical margins after radical prostatectomy: Does size matter? – A systematic review and meta-analysis	9
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	9
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer	9
Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy	9
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	9
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	9
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	9
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	9
The evolving standards of active surveillance monitoring	9
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	9

Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia	9
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry	9
The role of COVID-19 in prostate tissue inflammation: first pathological evidence	9
Correction: Germline alterations among Hispanic men with prostate cancer	9